Explore
Botulinum Toxin for Urinary Tract Disease
0 Ungluers have
Faved this Work
Login to Fave
Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are more practical ways of distribution on the way? What acceptance problems or obstacles to long-term use might exist among patients or doctors? What are the risks? Has the therapy gained a foothold in the outpatient sector?
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.